博士研究生学历，临床医学博士后，留美访问****，重庆市创新领军人才，重庆市中青年医学高端人才。先后主持各类科研项目20项，以第一作者或通讯作者发表中英文论文150余篇，出版专著1部，获得国家科技进步二等奖、重庆市科技进步一等奖、第三军医大学教学成果二等奖和军队科技进步四等奖各1项。近三年获得科研经费近4000万元。现为陆军军医大学博士生导师，西南大学博士生导师，遵义医科大学研究生导师，暨南大学兼职研究员、硕士研究生导师，川北医学院客座教授、研究生导师。
现任学术职务：国家卫生健康委员会艾滋病医疗专家组成员、国家临床医学中心评审专家、国家自然科学基金评审专家、中华中医药学会防治艾滋病分会常务委员、世界中医药学会联合会艾滋病分会常务理事、中华医学会感染病分会艾滋病学组委员、中华医学会热带病与寄生虫病分会艾滋病学组委员、中国医院协会传染病管理分会艾滋病综合管理学组副组长、重庆市艾滋病治疗专家组组长、重庆市性病艾滋病防治协会临床专委会主任委员、重庆市医学会感染病学专委会副主任委员、重庆市医院协会传染病管理专委会副主任委员和10余家SCI英文期刊特约审稿人。
近三年主持的科研项目：
1. 艾滋病机会性感染及难治性艾滋病精准诊治策略的研究（2018ZX**）， 起始时间：2018年1月，十三五国家科技重大专项，经费：3306.62万元。
2. 重庆MSM人群PrEP预防HIV感染的效果及影响因素研究（2017ZX**-001-011），起始时间：2017年1月，十三五国家科技重大专项，经费：108.6万元。
3. 新型冠状病毒肺炎临床救治策略研究与应用（cstc2020jscx-fyzx0074），起始时间：2020年1月，重庆市新冠肺炎应急科技攻关项目，经费：100万元。
4. 通过IP-10，MCP-1，IL-10优化IGRA鉴别诊断活动性结核和潜伏性结核的研究（cstc2018jcyjAX0428），起始时间：2018年8月，重庆市自然科学基金，经费：10万元。
5. 艾滋病合并隐球菌脑膜炎精准诊治计数研究（2019ZDXM012），起始时间：2019年9月，重庆市医学科研重点项目，经费：20万元。
6. 灸法治疗艾滋病免疫功能重建不良的前瞻性多中心随机对照研究（ZY），起始时间：2018年10月，重庆市中医药科技重点项目，经费：10万元。
7. 艾滋病合并机会性感染适宜诊疗技术的推广与应用（2018jstg031），起始时间：2018年8月，重庆市卫生适宜技术推广项目，经费：10万元。
近三年发表的部分论文：
1.Antibody Responses to SARS-CoV-2 in Patients With COVID-19. Nat Med. 2020 Apr 29. doi: 10.1038/s41591-020-0897-1. Online ahead of print. SCI: 30.641. Co-first author.
2.Human Monoclonal Antibodies Block the Binding of SARS-CoV-2 Spike Protein to Angiotensin Converting Enzyme 2 Receptor.Cell Mol Immunol. 2020 Apr 20;1-3. doi: 10.1038/s41423-020-0426-7. Online ahead of print. SCI: 8.213.Correspondence author.
3. HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer. Int J Biol Sci. 2019 Sep 7; 15(11):2438-2447. SCI: 4.067. Correspondence author.
4. The transcription factor T-Bet Is required for optimal type I follicular helper T cell maintenance during acute viral infection. Front Immunol. 2019 Mar 29; 10: 606. SCI: 5.511. Correspondence author.
5. Evaluation of blood-based antibody rapid testing for HIV early therapy: a meta-analysis of the evidence. Front Immunol. 2018 Jun 26; 9: 1458. SCI: 5.511. Correspondence author.
6. Molecular characterization of para-aminosalicylic acid resistant Mycobacterium tuberculosis clinical isolates in southwestern China. Infect Drug Resist. 2019 Jul 24; 12:2269-2275. SCI: 3.443. Correspondence author.
7. Assessing the efficacy of lopinavir/ritonavir-based preferred and alternative second-line regiments in HIV-infected patients：a meta-analysis of key evidence to support WHO recommendations. Front Pharmacol. 2018 Aug 14; 9: 890. SCI: 3.831. Correspondence author.
8. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J Infect Dis, 2020 Jan 25; 93: 108-117. SCI：3.831. Correspondence author.
9. Chemokine and cytokine cascade caused by skewing of the Th1-Th2 balance is associated with high intracranial pressure in HIV-associated cryptococcal meningitis. Mediators Inflamm. 2019 Dec 31; 2019: **. SCI: 3.57. Correspondence author.
10. Salidroside induces apoptosis and protective autophagy in human gastriccancer AGS cells through the PI3K/Akt/MTOR pathway. Biomedicine Pharmacotherapy, 2020 Feb; 122: 109726. SCI: 3.743. Correspondence author.
11. Efficacy and safety of raltegravir-based dual therapy in AIDS patients: a meta-analysis of randomized controlled trials. Front Pharmacol. 2019 Oct 17; 10: 1225. SCI: 3.845. Correspondence author.
12. The double burdens of mental health among AIDS patients with fully successful immune restoration: a cross-sectional study of anxiety and depression in China. Front Psychiatry. 2018 Aug 24; 9:384. SCI: 3.13. Correspondence author.
13. Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens: a meta-analysis of randomized controlled trials. Int J Infect Dis. 2019 Oct; 87: 43-53. SCI: 3.831. Correspondence author.
14. Rapid direct drug susceptibility testing of Mycobacterium tuberculosis based on culture droplet digital polymerase chain reaction. Int J Tuberc Lung Dis. 2019 Feb 1; 23(2): 219-225. SCI: 2.392. Correspondence author.
15. Metformin effect on gut microbiota: insights for HIV-related inflammation. AIDS Res Ther. 2020 Mar 10; 17(1):10. SCI: 2.270. Correspondence author.
16. Six weeks into the 2019 coronavirus disease outbreak: it is time to consider strategies to impede the emergence of new zoonotic infections. Chin Med J (Engl). 2020 Feb 24. doi: 10.1097/CM9.0760. [Epub ahead of print] SCI: 1.555. Correspondence author.
17. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus disease 2019: protocol of a randomized controlled trial. Chin Med J (Engl). 2020 Mar 5. doi: 10.1097/CM9.0791. [Epub ahead of print] SCI: 1.555. Correspondence author.
18. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia. Chin Med J (Engl). 2020 Mar 5. doi: 10.1097/CM9.0790. [Epub ahead of print] SCI: 1.555. Correspondence author.
19. The Bacterium Akkermansia muciniphila: A Sentinel for Gut Permeability and Its Relevance to HIV-Related Inflammation. Front Immunol. April 2020. doi: 10.3389/fimmu.2020.00645. SCI: 4.716. Correspondence author.
20. Potential therapeutic options for coronavirus disease 2019: using knowledge of past outbreaks to guide future treatment. Chin Med J (Engl). 2020 Mar 17. doi: 10.1097/CM9.0816. [Epub ahead of print]. SCI: 1.555. Correspondence author.
通讯地址：重庆市沙坪坝区保育路109号，重庆市公共卫生医疗救治中心 400036